SEC Tracker
Get the app

Celcuity CELC

Celcuity FY 2023: net loss $63.8M; diluted EPS −$2.69

Form
10-K
Filed
Period
Importance
Notable
Document
10-K

Key figures from this report

These are the numbers Celcuity reported for the year ended Dec 31, 2023, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.

  1. Net income−$63.8MAgainst −$40.4M in FY 202210-K income statement, on EDGAR
  2. Diluted EPS−$2.69Against −$2.64 in FY 202210-K income statement, on EDGAR
  3. Cash and cash equivalents$30.7M+25% from $24.6M in FY 2022Cash and equivalents only; the company page adds short-term investments.10-K balance sheet, on EDGAR
  4. Cash from operations−$53.8MAgainst −$36.0M in FY 202210-K cash flow statement, on EDGAR

Every year in the financial tables

View on EDGAR

Open in the app

Get an email when Celcuity files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 8071 and related industry codes: the same peer list as the financial tables.

  1. Fortrea Holdings FTRE public float $448M, Jun 30, 2025
  2. Castle Biosciences CSTL public float $576M, Jun 30, 2025
  3. Personalis PSNL public float $578M, Jun 30, 2025
  4. Fulgent Genetics FLGT public float $284M, Jun 30, 2025
  5. CareDx CDNA public float $1.0B, Jun 30, 2025